CpG expedites regression of local and systemic tumors when combined with activatable nanodelivery

J Control Release. 2015 Dec 28;220(Pt A):253-264. doi: 10.1016/j.jconrel.2015.10.016. Epub 2015 Oct 22.

Abstract

Ultrasonic activation of nanoparticles provides the opportunity to deliver a large fraction of the injected dose to insonified tumors and produce a complete local response. Here, we evaluate whether the local and systemic response to chemotherapy can be enhanced by combining such a therapy with locally-administered CpG as an immune adjuvant. In order to create stable, activatable particles, a complex between copper and doxorubicin (CuDox) was created within temperature-sensitive liposomes. Whereas insonation of the CuDox liposomes alone has been shown to produce a complete response in murine breast cancer after 8 treatments of 6 mg/kg delivered over 4 weeks, combining this treatment with CpG resolved local cancers within 3 treatments delivered over 7 days. Further, contralateral tumors regressed as a result of the combined treatment, and survival was extended in systemic disease. In both the treated and contralateral tumor site, the combined treatment increased leukocytes and CD4+ and CD8+ T-effector cells and reduced myeloid-derived suppressor cells (MDSCs). Taken together, the results suggest that this combinatorial treatment significantly enhances the systemic efficacy of locally-activated nanotherapy.

Keywords: CpG; Doxorubicin; Immunotherapy; Temperature-sensitive liposome; Ultrasound.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adjuvants, Immunologic / administration & dosage*
  • Adjuvants, Immunologic / chemistry
  • Animals
  • Antibiotics, Antineoplastic / administration & dosage*
  • Antibiotics, Antineoplastic / chemistry
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / immunology
  • Breast Neoplasms / pathology
  • CD4-Positive T-Lymphocytes / drug effects
  • CD4-Positive T-Lymphocytes / immunology
  • CD8-Positive T-Lymphocytes / drug effects
  • CD8-Positive T-Lymphocytes / immunology
  • Combined Modality Therapy
  • DNA / administration & dosage*
  • DNA / chemistry
  • Doxorubicin / administration & dosage*
  • Doxorubicin / chemistry
  • Drug Compounding
  • Female
  • Immunotherapy / methods*
  • Liposomes
  • Lymphocytes, Tumor-Infiltrating / drug effects
  • Lymphocytes, Tumor-Infiltrating / immunology
  • Macrophages / drug effects
  • Macrophages / immunology
  • Mice
  • Nanoparticles*
  • Nanotechnology
  • Organometallic Compounds / administration & dosage*
  • Organometallic Compounds / chemistry
  • Technology, Pharmaceutical / methods
  • Temperature
  • Time Factors
  • Tumor Burden / drug effects
  • Tumor Microenvironment
  • Ultrasonic Therapy / methods*

Substances

  • Adjuvants, Immunologic
  • Antibiotics, Antineoplastic
  • CpG phosphorothioate ODN 1826-S
  • Liposomes
  • Organometallic Compounds
  • doxorubicin-copper(II) complex
  • Doxorubicin
  • DNA